Celcuity (CELC) to Release Quarterly Earnings on Wednesday

Celcuity (NASDAQ:CELC) is expected to release its Q1 2026 results after the market closes on Wednesday, May 13th. Analysts expect Celcuity to post earnings of ($1.07) per share and revenue of $2.9390 million for the quarter. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:30 PM ET.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings data on Wednesday, March 25th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $0.09. On average, analysts expect Celcuity to post $-4 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Celcuity Stock Down 2.3%

Shares of CELC opened at $141.69 on Wednesday. The company has a debt-to-equity ratio of 3.20, a current ratio of 10.55 and a quick ratio of 10.55. The stock has a market capitalization of $6.85 billion, a price-to-earnings ratio of -37.39 and a beta of 0.09. Celcuity has a 1 year low of $9.51 and a 1 year high of $151.02. The business’s 50 day simple moving average is $115.27 and its 200-day simple moving average is $103.28.

Celcuity News Summary

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: Topline Phase 3 VIKTORIA‑1 results reportedly show gedatolisib improved progression‑free survival vs Novartis’ alpelisib in the PIK3CA‑mutant cohort — a direct efficacy win versus a marketed competitor that materially strengthens commercial prospects. Celcuity’s gedatolisib beats Novartis drug in Phase III test
• Positive Sentiment: Company says it will pursue a supplemental NDA filing for the PIK3CA‑mutant data and will present detailed results at ASCO — this creates a clear near‑term regulatory/visibility catalyst on top of the already accepted NDA for a different subgroup. Celcuity shares jump 15.5% as Phase 3 VIKTORIA-1 topline results support potential label expansion path for gedatolisib
• Positive Sentiment: Multiple analysts raised ratings/targets after the news (Needham to $157, Citizens/JMP to $160 and others), which likely amplified buying and gave investors new valuation anchors. Needham & Company LLC Issues Positive Forecast for Celcuity (NASDAQ:CELC) Stock Price
• Neutral Sentiment: Broad media coverage (MarketWatch, FierceBiotech, Yahoo/Finance) is increasing awareness ahead of ASCO and the upcoming PDUFA for the previously accepted NDA, pushing volumes and short‑term attention. Celcuity Shares Climb on Positive Breast-Cancer Drug Trial Results
• Neutral Sentiment: Clinical summaries and independent coverage recap VIKTORIA‑1 toplines and planned ASCO presentation; these reports inform but leave detailed subgroup and safety readouts pending (ASCO presentation will be important). Celcuity reports Phase III VIKTORIA-1 trial results for breast cancer
• Negative Sentiment: Insider selling has been reported recently (multiple open‑market sales), which some investors view as a cautionary signal despite positive trial news. Insider trading and institutional flow summary
• Negative Sentiment: High valuation and negative reported EPS mean the stock’s rally rests on future commercial execution and regulatory approvals; volatility and downside risk remain if upcoming ASCO or FDA updates disappoint. Valuation note

Insider Transactions at Celcuity

In other Celcuity news, Director Richard E. Buller sold 3,000 shares of Celcuity stock in a transaction on Tuesday, March 31st. The shares were sold at an average price of $110.27, for a total transaction of $330,810.00. Following the completion of the transaction, the director directly owned 6,760 shares of the company’s stock, valued at $745,425.20. The trade was a 30.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.33% of the stock is currently owned by corporate insiders.

Institutional Trading of Celcuity

Several institutional investors have recently added to or reduced their stakes in CELC. Xponance LLC bought a new position in shares of Celcuity during the fourth quarter valued at approximately $251,000. FORA Capital LLC bought a new stake in shares of Celcuity during the 3rd quarter worth approximately $248,000. Cibc World Markets Corp bought a new stake in shares of Celcuity during the 4th quarter worth approximately $212,000. CIBC Private Wealth Group LLC purchased a new position in Celcuity during the 4th quarter valued at $202,000. Finally, Perbak Capital Partners LLP purchased a new position in Celcuity during the 3rd quarter valued at $200,000. Institutional investors own 63.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on CELC. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celcuity in a research note on Monday, April 20th. Stifel Nicolaus set a $150.00 price objective on shares of Celcuity in a research note on Monday. Needham & Company LLC upped their target price on shares of Celcuity from $122.00 to $157.00 and gave the company a “buy” rating in a research report on Monday. Citigroup reaffirmed an “outperform” rating on shares of Celcuity in a report on Monday. Finally, Wall Street Zen lowered Celcuity from a “hold” rating to a “sell” rating in a research report on Saturday, April 25th. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $134.50.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.